1289197-78-9 Usage
General Description
2-bromo-4-chloronicotinaldehyde is a chemical compound with the molecular formula C7H4BrClNO. It is a yellow to brown solid that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 2-bromo-4-chloronicotinaldehyde is also used in organic synthesis as a building block for the production of various compounds. Its unique structure and reactivity make it a valuable tool for the development of new chemical entities and materials. However, it is important to handle this compound with care as it can be harmful if ingested or inhaled, and can cause skin and eye irritation upon contact.
Check Digit Verification of cas no
The CAS Registry Mumber 1289197-78-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,9,1,9 and 7 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1289197-78:
(9*1)+(8*2)+(7*8)+(6*9)+(5*1)+(4*9)+(3*7)+(2*7)+(1*8)=219
219 % 10 = 9
So 1289197-78-9 is a valid CAS Registry Number.
1289197-78-9Relevant articles and documents
BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY
-
Paragraph 0669-0670, (2021/05/15)
The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
BICYCLIC PIPERAZINE COMPOUNDS
-
Paragraph 0307, (2013/05/21)
Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
